Meta-analysis: Effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events

被引:78
作者
Bateman, Eric [1 ]
Nelson, Harold
Bousquet, Jean
Kral, Kenneth
Sutton, Laura
Ortega, Hector
Yancey, Steven
机构
[1] Univ Cape Town, Lung Inst, Dept Med, Div Pulmonol, ZA-7937 Cape Town, South Africa
关键词
D O I
10.7326/0003-4819-149-1-200807010-00229
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent analyses have suggested an increased risk for serious asthma-related adverse events in patients receiving longacting beta-agonists. Purpose: To examine whether the incidences of severe asthma-related events (hospitalizations, intubations, deaths, and severe exacerbations) differ in persons receiving salmeterol plus inhaled corticosteroids compared with inhaled corticosteroids alone. Data Sources: The GlaxoSmithKline (Research Triangle Park, North Carolina) database, MEDLINE, EMBASE, CINAHL, and the Cochrane Database of Systemic Reviews (1982 to September 2007) were searched without language restriction. Study Selection: Randomized, controlled trials reported in any language that compared inhaled corticosteroids plus salmeterol (administered as fluticasone propionate/salmeterol by means of a single device or concomitant administration of inhaled corticosteroids and salmeterol) versus inhaled corticosteroids alone in participants with asthma. Data Extraction: Three physicians independently reviewed and adjudicated blinded case narratives on serious adverse events that were reported in the GlaxoSmithKline trials. Data Synthesis: Data from 66 GlaxoSmithKline trials involving a total of 20 966 participants with persistent asthma were summarized quantitatively. The summary risk difference for asthma-related hospitalizations from these trials was 0.0002 (95% CI, -0.0019 to 0.00231; P = 0.84) for participants receiving inhaled corticosteroids plus salmeterol (n = 35 events) versus those receiving inhaled corticosteroids alone (n =34 events). One asthma- related intubation and 1 asthma- related death occurred among participants receiving inhaled corticosteroids with salmeterol; no such events occurred among participants receiving inhaled corticosteroids alone. A subset of 24 trials showed a decreased risk for severe asthma- related exacerbations for inhaled corticosteroids plus salmeterol versus inhaled corticosteroids alone (risk difference, -0.025 [CI, -0.036 to -0.014]; P < 0.001). Limitations: The included trials involved selected patients who received careful follow-up. Only 26 trials were longer than 12 weeks. Few deaths and intubations limited the ability to measure risk for these outcomes. Conclusion: Salmeterol combined with inhaled corticosteroids decreases the risk for severe exacerbations, does not seem to alter the risk for asthma- related hospitalizations, and may not alter the risk for asthma- related deaths or intubations compared with inhaled corticosteroids alone.
引用
收藏
页码:33 / +
页数:15
相关论文
共 79 条
[1]   Bronchodilator treatment and deaths from asthma: case-control study [J].
Anderson, HR ;
Ayres, JG ;
Sturdy, PM ;
Bland, JM ;
Butland, BK ;
Peckitt, C ;
Taylor, JC ;
Victor, CR .
BRITISH MEDICAL JOURNAL, 2005, 330 (7483) :117-120
[2]  
[Anonymous], GLAXOSMITHKLINE CLIN
[3]   Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma [J].
Aubier, M ;
Pieters, WR ;
Schlösser, NJJ ;
Steinmetz, KO .
RESPIRATORY MEDICINE, 1999, 93 (12) :876-884
[4]   Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma [J].
Baraniuk, J ;
Murray, JJ ;
Nathan, RA ;
Berger, WE ;
Johnson, M ;
Edwards, LD ;
Srebro, S ;
Rickard, KA .
CHEST, 1999, 116 (03) :625-632
[5]   Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down [J].
Bateman, ED ;
Jacques, L ;
Goldfrad, C ;
Atienza, T ;
Mihaescu, T ;
Duggan, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (03) :563-570
[6]   Can guideline-defined asthma control be achieved? The gaining optimal asthma control study [J].
Bateman, ED ;
Boushey, HA ;
Bousquet, J ;
Busse, WW ;
Clark, TJH ;
Pauwels, RA ;
Pedersen, SE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (08) :836-844
[7]   Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 μg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma [J].
Bateman, ED ;
Silins, V ;
Bogolubov, M .
RESPIRATORY MEDICINE, 2001, 95 (02) :136-146
[8]  
Bergmann KC, 2004, SWISS MED WKLY, V134, P50
[9]   Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events [J].
Bradburn, Michael J. ;
Deeks, Jonathan J. ;
Berlin, Jesse A. ;
Localio, A. Russell .
STATISTICS IN MEDICINE, 2007, 26 (01) :53-77
[10]   Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily [J].
Busse, W ;
Koenig, SM ;
Oppenheimer, J ;
Sahn, SA ;
Yancey, SW ;
Reilly, D ;
Edwards, LD ;
Dorinsky, PM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (01) :57-65